{"id":14761,"date":"2025-06-23T16:04:02","date_gmt":"2025-06-23T14:04:02","guid":{"rendered":"https:\/\/copolad.eu\/?p=14761"},"modified":"2025-09-22T12:35:13","modified_gmt":"2025-09-22T10:35:13","slug":"euda-report-2025","status":"publish","type":"post","link":"https:\/\/copolad.eu\/en\/euda-report-2025\/","title":{"rendered":"Ensuring Europe\u2019s preparedness for evolving drug problems"},"content":{"rendered":"<p><a href=\"https:\/\/www.euda.europa.eu\/system\/files\/documents\/2025-06\/edr-2025-full-book-6.06.2025-en.pdf\">The <em data-start=\"258\" data-end=\"285\">European Drug Report 2025<\/em><\/a>, the EUDA\u2019s annual overview of the drug situation, highlights a market that remains resilient while increasingly shaped by global developments. Both established and emerging illicit drugs \u2014 and the growing interplay between them \u2014 continue to fuel serious health and security challenges, creating a complex policy environment for effective responses.<\/p>\n<h3 class=\"p1\">Increased availability of substances<\/h3>\n<p>The European drug market is evolving rapidly as both suppliers and consumers are finding ways to adapt to geopolitical instability, globalisation and technological advances. This appears to be resulting in the availability of a more diverse range of substances, often of high potency and purity, which are posing new risks to public health. At the same time global events threaten to push Europe&#8217;s response capacities to the limit, as the complexity and scale of the problem continue to grow.<\/p>\n<p>The impact of the developments we are seeing means that <b>everyone is in some way likely to be affected by illicit drug use, the operation of the drug market and the problems associated with it<\/b>. Directly, we see this in those who develop problems and need treatment or other services. Indirectly, we see it in the recruitment into criminality of vulnerable young people, the strain on health budgets, and the social costs for communities that feel unsafe or where institutions or businesses are undermined by <b>corruption or criminal practices<\/b>. We cannot avoid the fact that drug issues have an impact almost everywhere.<\/p>\n<p>They are manifest in and exacerbate other complex policy problems, such as homelessness, the management of psychiatric disorders and youth criminality. We are also witnessing greater levels of violence and corruption driven by the drug market in some countries. Increasingly, we are observing that almost everything with <b>psychoactive properties<\/b> can appear on the drug market, often mislabelled or in mixtures, leaving consumers potentially unaware of what they are using, increasing health risks and creating new law-enforcement and regulatory challenges.<\/p>\n<p><img decoding=\"async\" class=\"size-large wp-image-14757\" src=\"https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107-1024x858.jpg\" alt=\"M\u00e9todos de tr\u00e1fico de drogas. Fuente: EUDA\" width=\"1024\" height=\"858\" srcset=\"https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107-1024x858.jpg 1024w, https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107-300x251.jpg 300w, https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107-768x643.jpg 768w, https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107-750x628.jpg 750w, https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107-1140x955.jpg 1140w, https:\/\/copolad.eu\/wp-content\/uploads\/2025\/06\/img4107.jpg 1189w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/p>\n<h3 class=\"p1\">Reinforce preparedness<\/h3>\n<p>The EUDA is committed to <b>increasing Europe\u2019s preparedness on illicit drugs and new psychoactive substances<\/b>, supporting the European Union and its Member States through a new, interconnected service model. The European Drug Report supports this work by highlighting the latest trends and emerging threats for policymakers and practitioners in the drugs field, in order to inform their efforts and support the development of evidence-based and timely responses to new and changing drug problems.<\/p>\n<h3>The\u00a0<em>European Drug Report<\/em> 2025 provides a snapshot of the drug situation in Europe based on the latest data available. You can consult the different sections here:<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/drug-situation-in-europe-up-to-2025_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"cf3153e2-db9d-4502-afef-1ce951f5467c\"><strong>Understanding Europe\u2019s drug situation in 2025 \u2013 key developments<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/drug-supply-production-and-precursors_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8b376de0-e6ac-4ec6-abdd-9ed0fa01863c\"><strong>Drug supply, production and precursors \u2013 the current situation in Europe\u00a0<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/cannabis_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"be04740c-463e-4561-86a1-5b026d31c268\"><strong>Cannabis \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/cocaine_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"41ada351-0eab-45b9-97f5-f910d383f18c\"><strong>Cocaine \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/synthetic-stimulants_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d8a11c24-cb00-4a7f-8242-ae2d4c2db31c\"><strong>Synthetic stimulants \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/mdma_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e5abe08f-805f-4cbe-bdeb-46c0b2140849\"><strong>MDMA \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/Heroin%20and%20other%20opioids%20%E2%80%93%20the%20current%20situation%20in%20Europe%20(European%20Drug%20Report%202025)\"><strong>Heroin and other opioids \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/new-psychoactive-substances_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"528243b3-6c53-496c-9e24-feefe0becfd4\"><strong>New psychoactive substances \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/other-drugs_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"7d056e9d-2e35-4978-8173-02c071f5749b\"><strong>Other drugs \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/injecting-drug-use_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"ecdad62e-7338-4df3-a10b-99d64fc2c20e\"><strong>Injecting drug use \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/drug-related-infectious-diseases_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"2e75bad3-5de6-4b56-9e26-d1d210c3c892\"><strong>Drug-related infectious diseases \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/drug-induced-deaths_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"25170f6e-d322-474d-bdc0-89912421fb00\"><strong>Drug-induced deaths \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/opioid-agonist-treatment_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"86c2b037-b797-4279-9ec7-b6dd3e16f99f\"><strong>Opioid agonist treatment \u2013 the current situation in Europe<\/strong>\u00a0<\/a><\/li>\n<li><strong><u><a href=\"https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/harm-reduction_en\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"a35b8a0b-c76b-4c3a-b5e5-b846a745e3ac\">Harm reduction \u2013 the current situation in Europe\u00a0<\/a><\/u><\/strong><\/li>\n<\/ul>\n<h3><a href=\"https:\/\/www.euda.europa.eu\/system\/files\/documents\/2025-06\/edr-2025-full-book-6.06.2025-en.pdf\"><strong>Download full PDF version of the\u00a0European Drug Report 2025<\/strong><\/a><\/h3>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Drug Report 2025, the EUDA\u2019s annual overview of the drug situation, highlights a market that remains resilient while increasingly shaped by global developments. Both established and emerging illicit drugs \u2014 and the growing interplay between them \u2014 continue to fuel serious health and security challenges, creating a complex policy environment for effective responses. [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":14759,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"The EUDA\u2019s latest report reveals a market that is both resilient and influenced by developments taking place at the global level","format":"standard","override":[{"template":"3","parallax":"1","fullscreen":"1","layout":"no-sidebar","sidebar":"default-sidebar","second_sidebar":"default-sidebar","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_featured":"1","show_post_meta":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"0","post_reading_time_wpm":"300","post_calculate_word_method":"str_word_count","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"0","show_inline_post_related":"0"}],"image_override":[{"single_post_thumbnail_size":"crop-715","single_post_gallery_size":"crop-715"}],"trending_post_position":"meta","trending_post_label":"Trending","sponsored_post_label":"Sponsored by","disable_ad":"0"},"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":{"view_counter_number":"0","share_counter_number":"0","like_counter_number":"0","dislike_counter_number":"0"},"jnews_post_split":{"post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[102],"tags":[304],"class_list":["post-14761","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-drug-research"],"acf":[],"_links":{"self":[{"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/posts\/14761"}],"collection":[{"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/comments?post=14761"}],"version-history":[{"count":3,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/posts\/14761\/revisions"}],"predecessor-version":[{"id":14985,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/posts\/14761\/revisions\/14985"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/media\/14759"}],"wp:attachment":[{"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/media?parent=14761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/categories?post=14761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/copolad.eu\/en\/wp-json\/wp\/v2\/tags?post=14761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}